Drug intelligence / Profile preview

SDC-1802

Development stage: Unknown
Lead developer: Sareum
Modality: Small Molecules
Administration: Oral

Overview

SDC-1802 is an orally available, small molecule dual inhibitor of tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1), developed by Sareum. It is designed to block the activity of these kinases with high selectivity over related JAK family members. The drug demonstrates anti-tumor activity in preclinical models of several cancer types—including T-cell acute lymphoblastic leukemia (T-ALL), B-cell lymphoma, renal cell carcinoma, and solid tumors—by a novel immunotherapeutic mechanism that reduces tumor growth. SDC-1802 is currently in preclinical development for cancer indications and has also been considered for systemic lupus erythematosus[1][3][6][8].

Other names: SDC 1802SDC1802SDC-1802SAR 20351SAR20351SAR-20351

Targets

JAK1 (Janus kinase 1)TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on SDC-1802.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SDC-1802.

Explore the full profile